$BMRA
BIOMERICA INC Stock $bmra

$bmra Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223037070 Filed on October 12, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$1.567M	$1.713M	$1.637M
YoY Change	5.74%	4.64%	29.74%
Cost Of Revenue	$1.242M	$1.301M	$1.692M
YoY Change	9.91%	-23.13%	25.29%
Gross Profit	$325.0K	$412.0K	-$54.96K
YoY Change	-7.64%	-849.7%	-38.23%
Gross Profit Margin	20.74%	24.05%	-3.36%
Selling, General & Admin	$1.521M	$1.172M	$1.654M
YoY Change	-2.25%	-29.13%	63.5%
% of Gross Profit	468.0%	284.47%
Research & Development	$412.0K	$472.0K	$361.0K
YoY Change	-10.82%	30.75%	-17.93%
% of Gross Profit	126.77%	114.56%
Depreciation & Amortization	$19.00K	$21.00K	$20.00K
YoY Change	18.75%	5.0%	-42.4%
% of Gross Profit	5.85%	5.1%
Operating Expenses	$1.933M	$1.644M	$2.015M
YoY Change	-4.21%	-18.41%	38.83%
Operating Profit	-$1.608M	-$1.232M	-$2.070M
YoY Change	-3.49%	-40.48%	34.38%
Interest Expense	$109.0K	$120.0K	$30.00
YoY Change	164.24%	399900.0%	-99.56%
% of Operating Profit
Other Income/Expense, Net	$109.0K	$123.0K	$28.00
YoY Change	164.24%	439185.71%	-99.59%
Pretax Income	-$1.499M	-$1.109M	-$2.070M
YoY Change	-7.74%	-46.42%	34.97%
Income Tax	$8.000K	$23.00K	$1.957K
% Of Pretax Income
Net Earnings	-$1.507M	-$1.132M	-$2.072M
YoY Change	-7.32%	-45.36%	34.31%
Net Earnings / Revenue	-96.17%	-66.08%	-126.57%
Basic Earnings Per Share	-$0.09	-$0.07	-$0.16
Diluted Earnings Per Share	-$0.09	-$0.07	-$0.16
COMMON SHARES
Basic Shares Outstanding	16.82M shares	16.82M shares	13.39M shares
Diluted Shares Outstanding	16.82M shares	16.82M shares	13.10M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.134M	$7.990M	$6.075M
YoY Change	40.81%	31.52%	21.58%
Cash & Equivalents	$7.134M	$7.988M	$6.075M
Short-Term Investments
Other Short-Term Assets	$223.0K	$280.0K	$238.8K
YoY Change	84.72%	17.27%	-24.26%
Inventory	$1.841M	$1.877M	$1.922M
Prepaid Expenses
Receivables	$1.067M	$1.430M	$932.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$10.27M	$11.57M	$9.168M
YoY Change	26.75%	26.25%	2.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$210.0K	$218.0K	$227.9K
YoY Change	-11.29%	-4.35%	-87.18%
Goodwill
YoY Change
Intangibles	$204.0K	$202.0K	$160.8K
YoY Change	29.36%	25.66%
Long-Term Investments	$165.0K	$170.0K	$165.3K
YoY Change	-0.19%	2.83%	0.0%
Other Assets	$96.00K	$96.00K	$93.51K
YoY Change	20.52%	2.66%	-64.92%
Total Long-Term Assets	$1.566M	$1.645M	$1.882M
YoY Change	-13.43%	-12.61%	-26.77%
TOTAL ASSETS
Total Short-Term Assets	$10.27M	$11.57M	$9.168M
Total Long-Term Assets	$1.566M	$1.645M	$1.882M
Total Assets	$11.83M	$13.22M	$11.05M
YoY Change	19.41%	19.63%	-4.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$783.0K	$710.0K	$671.2K
YoY Change	16.85%	5.77%	4.65%
Accrued Expenses	$979.0K	$970.0K	$935.8K
YoY Change	-6.24%	3.65%	11.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.822M	$1.746M	$1.758M
YoY Change	3.33%	-0.66%	18.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$626.0K	$710.0K	$970.9K
YoY Change	-30.56%	-26.87%	-21.12%
Total Long-Term Liabilities	$626.0K	$710.0K	$970.9K
YoY Change	-30.56%	-26.87%	-21.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.822M	$1.746M	$1.758M
Total Long-Term Liabilities	$626.0K	$710.0K	$970.9K
Total Liabilities	$2.448M	$2.451M	$2.728M
YoY Change	-8.13%	-10.17%	0.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$44.86M	-$43.30M	-$37.15M
YoY Change	15.61%	16.56%
Common Stock	$1.346M	$1.346M	$1.073M
YoY Change	24.82%	25.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.383M	$10.77M	$8.322M
YoY Change
Total Liabilities & Shareholders Equity	$11.83M	$13.22M	$11.05M
YoY Change	19.41%	19.63%	-4.05%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$1.507M	-$1.132M	-$2.072M
YoY Change	-7.32%	-45.36%	34.31%
Depreciation, Depletion And Amortization	$19.00K	$21.00K	$20.00K
YoY Change	18.75%	5.0%	-42.4%
Cash From Operating Activities	-$846.0K	-$1.674M	-$1.573M
YoY Change	-30.27%	6.4%	-2174.52%
INVESTING ACTIVITIES
Capital Expenditures	$15.00K	$21.00K	$33.62K
YoY Change	-161.27%	-37.54%	-143.37%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$15.00K	-$63.00K	-$33.62K
YoY Change	-38.73%	87.37%	-56.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		$1.778M
YoY Change	-100.0%		120.92%
NET CHANGE
Cash From Operating Activities	-846.0K	-$1.674M	-$1.573M
Cash From Investing Activities	-15.00K	-$63.00K	-$33.62K
Cash From Financing Activities	0.000		$1.778M
Net Change In Cash	-861.0K	-$1.731M	$158.1K
YoY Change	-13.86%	-1195.2%	-80.32%
FREE CASH FLOW
Cash From Operating Activities	-$846.0K	-$1.674M	-$1.573M
Capital Expenditures	$15.00K	$21.00K	$33.62K
Free Cash Flow	-$861.0K	-$1.695M	-$1.607M
YoY Change	-27.57%	5.48%	-1147.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000073290
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating		usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2022Q3	BMRA	Stock Issued During Period Value Shares Issued In Connection With Public Offering StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOffering		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q3	BMRA	Stock Issued During Period Value Shares Issued In Connection With Public Offering StockIssuedDuringPeriodValueSharesIssuedInConnectionWithPublicOffering		usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability		usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q3	BMRA	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost		usd
CY2023Q3	BMRA	Write Off Of Reserved Inventory WriteOffOfReservedInventory		usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost		usd
CY2023Q3	BMRA	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-08-31
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	001-37863
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	BIOMERICA, INC.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-2645573
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	17571 Von Karman Avenue
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Irvine
CY2023Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92614
CY2023Q3	dei	City Area Code CityAreaCode	949
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	645-2111
CY2023Q3	dei	Security12b Title Security12bTitle	Common Stock, par value $0.08
CY2023Q3	dei	Trading Symbol TradingSymbol	BMRA
CY2023Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16821646	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7988000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9719000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1430000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	722000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1877000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2056000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	279000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	11574000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	12797000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	218000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	213000	usd
CY2023Q3	BMRA	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	688000	usd
CY2023Q2	BMRA	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	617000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	964000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1035000	usd
CY2023Q3	us-gaap	Investments Investments	165000	usd
CY2023Q2	us-gaap	Investments Investments	165000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	202000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	165000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	96000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79000	usd
CY2023Q3	us-gaap	Assets Assets	13219000	usd
CY2023Q2	us-gaap	Assets Assets	14454000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	713000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	892000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	667000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	696000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	60000	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	60000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	306000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1746000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1945000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	705000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	785000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2451000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2730000	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4428571	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4428571	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.08
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16821646	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16821646	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16821646	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16821646	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	1346000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1346000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52875000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	52705000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-104000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-110000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43349000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-42217000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10768000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13219000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14454000	usd
CY2023Q3	us-gaap	Revenues Revenues	1713000	usd
CY2022Q3	us-gaap	Revenues Revenues	1637000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1301000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	1692000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	412000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	-55000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1172000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1654000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	472000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1644000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2015000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1232000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2070000	usd
CY2023Q3	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	123000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	123000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1109000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2070000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1132000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2072000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16821646	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13100407	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16821646	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13100407	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1132000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2072000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-13000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1126000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2085000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	8325000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1764000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-13000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	304000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2072000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	8322000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	11724000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	6000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	170000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1132000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10768000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	10768000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1132000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2072000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	29000	usd
CY2022Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	230000	usd
CY2023Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	-140000	usd
CY2022Q3	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	136000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	170000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	304000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	71000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	67000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	708000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	388000	usd
CY2023Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-319000	usd
CY2022Q3	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-358000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-21000	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-82000	usd
CY2023Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	17000	usd
CY2022Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-179000	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-301000	usd
CY2023Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-29000	usd
CY2022Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-55000	usd
CY2022Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	100000	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-71000	usd
CY2022Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-65000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1674000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1573000	usd
CY2023Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	usd
CY2022Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	usd
CY2023Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	42000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1811000	usd
CY2022Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	47000	usd
CY2022Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14000	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1778000	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6000	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-13000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1731000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	158000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9719000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5917000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7988000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6075000	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	23000	usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	usd
CY2022Q3	BMRA	Write Off Of Intangible Assets Cost WriteOffOfIntangibleAssetsCost	6000	usd
CY2022Q3	BMRA	Write Off Of Reserved Inventory WriteOffOfReservedInventory	1000	usd
CY2023Q3	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80E_eus-gaap--BasisOfAccounting_zCGWKo11Oio6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_829_zAoIPvQx3iFl">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biomerica, Inc. and its subsidiaries (which includes wholly-owned subsidiaries, Biomerica de Mexico and BioEurope GmbH) is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (physicians’ offices and over-the-counter through drugstores and online) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. Our diagnostic test kits are used to analyze blood, urine, nasal or fecal material from patients in the diagnosis of various diseases, food intolerances and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which may exist in the human body in extremely small concentrations. The Company’s products are designed to enhance the health and well-being of people, while reducing total healthcare costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (“DGT”) products based on our inFoods<sup>®</sup> Technology platform that treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. These inFoods<sup>®</sup> based products are directed at chronic inflammatory illnesses that are widespread and common, and as such address very large markets. The first product we are launching using this patented inFoods Technology is our inFoods<sup>®</sup> IBS product which uses a simple blood sample to identify patient-specific foods that, when removed from their diet, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping and constipation. Instead of broad and difficult to manage dietary restrictions, the inFoods® IBS product works by identifying a patient’s above normal immunoreactivity to a panel of specific foods that have been shown to often be problematic to IBS sufferers. A food identified as positive (causing an abnormally high immune response in the patient) is simply removed from the diet to help alleviate IBS symptoms. We have launched this product with certain large gastroenterology (“GI”) physician groups that are now offering this product to their patients. We have also recently hired an internal sales force to sign up additional GI physician groups who are interested in offering this product to their patients. As such, we are expecting material growth in revenues from the launch of our inFoods<sup>®</sup> IBS product in coming quarters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our other existing medical diagnostic products are sold worldwide primarily in two markets: 1) clinical laboratories and 2) point-of-care (physicians’ offices and over-the-counter at Walmart, Amazon, and Walgreens). The diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens, or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the global 2019 SARS-CoV-2 novel coronavirus pandemic, in March 2020 we began developing COVID-19 products to indicate if a person has been infected by COVID-19 or is currently infected. While we initially offered a COVID-19 antibody diagnostic test to determine if a person has previously been infected by the COVID-19 virus, all of our COVID-19 revenues in fiscal 2022 and 2023 have come from international sales of our COVID-19 antigen tests that use a patient’s nasal fluid sample to detect if the patient is currently infected with the virus. Due to falling demand, there were no sales of our COVID-19 related products in the three months ended August 31, 2023. As such, our COVID-19 product sales have caused significant swings in our revenues over the past eight quarters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our non-COVID-19 products that accounted for all of our revenues during the three months ended August 31, 2023, are primarily focused on gastrointestinal diseases, colorectal diseases, food intolerances, and certain esoteric tests. These diagnostic test products utilize immunoassay technology. Most of our products are CE marked and/or sold for diagnostic use where they are registered by each country’s regulatory agency. In addition, some products are cleared for sale in the United States by the FDA.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed consolidated financial statements herein have been prepared by management pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The accompanying unaudited condensed consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the latest fiscal year ended May 31, 2023. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended August 31, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending May 31, 2024. For further information, refer to the audited consolidated financial statements and notes thereto for the fiscal year ended May 31, 2023 included in the Company’s Annual Report on Form 10-K filed with the SEC on August 25, 2023. Management has evaluated all subsequent events and transactions through the date of filing this report.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zQylLZrUbi1l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zFBCopD3kkll">ACCOUNTING ESTIMATES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reported period. Estimates that are made include the allowance for doubtful accounts, which is estimated based on current as well as historical practices with a customer; stock option forfeiture rates, which are calculated based on historical data; inventory obsolescence, which is based on projected and historical usage of materials; and lease liability and right-of-use assets, which are calculated based on certain assumptions such as borrowing rate, the likelihood of lease extensions to occur, asset valuation, among other things; and other items that may be necessary to estimate using current, historical and judgment based information. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43300000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7988000	usd
CY2023Q3	BMRA	Working Capital WorkingCapital	-9828000	usd
CY2020Q3	BMRA	Shelf Registration Statement Maximum Authorized Common Stock Issuance Value ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue	90000000	usd
CY2023Q3	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_z45LZAhf4EPh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zH5YWDEaBiOf">CONCENTRATION OF CREDIT RISK</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances at certain financial institutions in excess of amounts insured by federal agencies. From time to time, the Company has uninsured balances. The Company does not believe it is exposed to any significant credit risks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated net sales were approximately $<span id="xdx_906_eus-gaap--Revenues_c20230601__20230831_z5FWzQ00xGta" title="Revenues">1,713,000</span> for the three months ended August 31, 2023, as compared to $<span id="xdx_90D_eus-gaap--Revenues_c20220601__20220831_zgxZ933Re2Q" title="Revenues">1,637,000</span> for the three months ended August 31, 2022. For the three months ended August 31, 2023 and 2022, the Company had one and two key customers who are located in foreign countries which accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20230831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustomerOneMember_zqpND7M0Vw7c" title="Concentration risk, percentage">59%</span> and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20220831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustomerTwoMember_zUegLzEafQF1" title="Concentration risk, percentage">64%</span> of net sales, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total gross receivables on August 31, 2023 and May 31, 2023 were approximately $<span id="xdx_90C_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230831_zSYVDkl0FK14" title="Other receivables, gross, current">1,459,000</span> and $<span id="xdx_905_eus-gaap--OtherReceivablesGrossCurrent_iI_c20230531_zBvlDtN6qsHl" title="Other receivables, gross, current">751,000</span>, respectively. On August 31, 2023 and May 31, 2023, the Company had one key customer, who are located in foreign countries which accounted for a total of <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20230831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneCustomerMember_zwqiOkzQoAjf" title="Concentration risk, percentage">67%</span> and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneCustomerMember_zclSH2SRaU83" title="Concentration risk, percentage">35%</span>, respectively, of gross accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended August 31, 2023 and 2022, the Company had one key vendor which accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20230831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zvJAwAKZMAId" title="Concentration risk, percentage">12%</span> and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20220831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zNQPJiaeRRy" title="Concentration risk, percentage">9%</span> of the purchases of raw materials, respectively. As of August 31, 2023 and May 31, 2023, the Company had one key vendor which accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230601__20230831__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zPbq4pmxP37c" title="Concentration risk, percentage">47%</span> and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220601__20230531__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OneVendorMember_zpt6inOtD476" title="Concentration risk, percentage">23%</span>, respectively, of accounts payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Revenues Revenues	1713000	usd
CY2022Q3	us-gaap	Revenues Revenues	1637000	usd
CY2023Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	1459000	usd
CY2023Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	751000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.52
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	68000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.18
CY2023Q3	BMRA	Accounts Receivable Credit Loss Expense Reversal AccountsReceivableCreditLossExpenseReversal	29000	usd
CY2023Q2	BMRA	Accounts Receivable Credit Loss Expense Reversal AccountsReceivableCreditLossExpenseReversal	29000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	279000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	300000	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1454000	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1677000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	793000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	869000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	162000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	182000	usd
CY2023Q3	us-gaap	Inventory Gross InventoryGross	2409000	usd
CY2023Q2	us-gaap	Inventory Gross InventoryGross	2728000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	532000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	672000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1877000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2056000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	532000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	672000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	47500	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.31
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2363116	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.45
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9000	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	6000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	170000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	304000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2342616	shares
CY2023Q3	us-gaap	Proceeds From Customers ProceedsFromCustomers	60000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1713000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1637000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	472000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	361000	usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	23000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	5000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	96000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	92000	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	30000	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	18000	usd
CY2023Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q3	us-gaap	Revenues Revenues	1713000	usd
CY2022Q3	us-gaap	Revenues Revenues	1637000	usd
CY2023Q3	us-gaap	Area Of Land AreaOfLand	22000	sqft
CY2023Q3	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On November 30, 2015, the Company exercised its option to extend its lease for an additional sixty-month period and entered into the First Amendment to Lease wherein it extended its lease until August 31, 2021. On April 9, 2021, the Company exercised its second option to extend its lease for an additional five years. When the Company extended its lease in April 2021, it was also granted an additional five-year lease extension option
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	22000	usd
CY2016Q4	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	In November 2016, the Company’s Mexican subsidiary, Biomerica de Mexico, entered into a 10-year lease for approximately 8,100 square feet of manufacturing space. The Company has one 10-year option to renew at the end of the initial lease period. Biomerica de Mexico also leases a smaller unit on a month-to-month basis for use in one manufacturing process.
CY2016Q4	us-gaap	Area Of Land AreaOfLand	8100	sqft
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	88000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	88000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	359000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	368000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	378000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1111000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	100000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1011000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	87000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	86000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure

Files In Submission

Name	View Source	Status
0001493152-23-037070-index-headers.html	Edgar Link	pending
0001493152-23-037070-index.html	Edgar Link	pending
0001493152-23-037070.txt	Edgar Link	pending
0001493152-23-037070-xbrl.zip	Edgar Link	pending
bmra-20230831.xsd	Edgar Link	pending
ex3-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bmra-20230831_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmra-20230831_def.xml	Edgar Link	unprocessable
bmra-20230831_lab.xml	Edgar Link	unprocessable
bmra-20230831_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRA
BIOMERICA INC Stock $bmra

2023 Q4 Form 10-Q Financial Statement

#000149315223037070 Filed on October 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA BIOMERICA INC Stock $bmra

2023 Q4 Form 10-Q Financial Statement

#000149315223037070 Filed on October 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRA
BIOMERICA INC Stock $bmra